| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8734666 | Revista Brasileira de Hematologia e Hemoterapia | 2017 | 8 Pages |
Abstract
The clinical trial met its primary objective of demonstrating an acceptable safety profile for SANGUINATE in patients with sickle cell anemia. This trial established the safety of SANGUINATE at both dose levels and permitted its advance to Phase II trials.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Hemant Misra, James Bainbridge, John Berryman, Abraham Abuchowski, Kenneth Mauricio Galvez, Luis Fernando Uribe, Angel Luis Hernandez, Nestor Rodolfo Sosa,